Group 1 - Nanyang City has launched an action plan to develop a biomanufacturing pilot zone, focusing on project traction, platform construction, and element guarantee to accelerate the transformation and industrial application of scientific research achievements [1] - The Henan Qianmu Biopharmaceutical Project, jointly invested by Qianhong Pharmaceutical and Muyuan Group, has been put into production, filling the gap in high-end heparin raw materials in Henan Province and integrating Nanyang's biopharmaceutical industry into the global value chain [1] - Nanyang has 46 biopharmaceutical enterprises above designated size, with an estimated total industry chain output value of approximately 40 billion yuan in 2024, and 25 provincial-level innovation platforms, supporting a full chain from R&D to pilot testing to industrialization [1] Group 2 - Nanyang is actively developing synthetic biology, leveraging the talent and technological advantages of the Nanyang Synthetic Biology Research Institute to create a new generation of efficient, low-consumption, and green bioprocessing platforms [1] - The city is focusing on the industrialization of high-efficiency biosynthesis projects for essential amino acids and microbial synthesis of oils, as well as the development of high-end bio-based materials and new food products like "artificial protein" [1] - The construction of strategic leading laboratories is being strengthened, with the first technology transfer project from the Nanyang pilot base entering mass production, expected to generate an annual output value of about 240 million yuan [2] Group 3 - Nanyang has established a technology innovation system that integrates production, education, research, and application, relying on key research platforms like Muyuan Laboratory and local universities [2] - The city has formed a favorable development pattern characterized by leading enterprises, chain-driven growth, strong product R&D capabilities, and wide market coverage in the biomanufacturing industry [2]

Group 1 - The core viewpoint of the article is that Nanyang City is actively developing a biomanufacturing industry by implementing an action plan that focuses on project traction, platform construction, and element guarantee to transform research achievements into industrial applications [1][2] - The establishment of the Henan Qianmu Biopharmaceutical project, a joint investment by Qianhong Pharmaceutical and Muyuan Group, fills the gap in high-end heparin raw materials in Henan Province and integrates Nanyang's biopharmaceutical industry into the global value chain [1] - Nanyang currently has 46 biopharmaceutical enterprises above designated size, with an expected total industry chain output value of approximately 40 billion yuan in 2024 [1] Group 2 - Nanyang is enhancing its strategic laboratory construction, with the Muyuan Laboratory's "one center, one base" development model and the Zhengzhou R&D center operating in an orderly manner [2] - The first technology transfer project from Nanyang's pilot base, the "Muyuan Anliang Isolucine Project," is expected to achieve an annual output value of about 240 million yuan [2] - The city is building a technology innovation system that integrates production, education, research, and application, leveraging the advantages of key research platforms and local universities [2]

Core Viewpoint - In 2024, the company reported its first annual loss since its listing, with a net profit of -56.55 million yuan, attributed to industry adjustments, new capacity investments, and increased expenses [2][5] Financial Performance - Revenue for 2024 was 278 million yuan, a decrease of 20.92% year-on-year [2][12] - The net profit attributable to shareholders was -56.55 million yuan, marking a 309.69% decline compared to the previous year [12] - The company recorded asset impairment losses totaling 34.84 million yuan, with 27.26 million yuan related to accounts receivable [2] Business Operations - The company plans to enhance its cash flow by pursuing legal actions to expedite receivables collection, with accounts receivable amounting to 211 million yuan as of the end of Q1 [2] - The company’s main business includes the production and sale of biological feed products and inorganic solid waste treatment services [2] Strategic Initiatives - The company aims to develop synthetic biology as its third growth curve, focusing on early-stage quality projects through cautious investments [2][7] - The company has rebranded from "Lude Environmental Technology Co., Ltd." to "Lude Biological Environmental Technology Co., Ltd." to reflect its business transformation [5] Market Position and Future Outlook - The biological fermentation feed business generated 217 million yuan in revenue, accounting for 78.11% of total revenue, an increase of 31.80 percentage points from 2022 [5] - The company has expanded its production capacity from one factory to five, with a total capacity of 470,000 tons per year, and plans to increase it to 1 million tons [6][7] - The company expects stable growth in revenue and net profit for 2025, driven by the synthetic biology sector, particularly in beauty and functional food applications [7]